The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil – home
18 December, 201720th edition of the RedETSA Webinars program
March 20, 2018Saiu Pharma Report Brazil 2018, with interviews with two representatives of the industry, the Ministry of Health, the president of Anvisa and the Secretary of SCMED.
Access the link: https://pharmaboardroom.com/pharma_report/brazil-pharma-report-2018/
English 
Español 
Português do Brasil